Valuation: Novacyt

Market Cap 34.51M 39.82M 32.31M 29.48M 55.47M 3.8B 56.41M 379M 148M 1.9B 150M 146M 6.34B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 36.47M 42.08M 34.14M 31.15M 58.62M 4.01B 59.6M 400M 157M 2.01B 158M 155M 6.7B EV / Sales 2026 *
1.19x
EV / Sales 2027 * 1.13x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-27.49%
1 week+12.50%
Current month+12.50%
1 month+12.50%
3 months+12.50%
6 months+12.50%
Current year+5.86%
Current year 0.48
Extreme 0.48
0.54
1 year 0.48
Extreme 0.48
0.54
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-27.49%+12.50% - - 39.82M
+1.17%+1.17%-38.64%-42.78% 630M
-0.14%-2.92%+131.30% - 430M
+1.70%+15.93%-29.45%-11.09% 140M
0.00%-5.74%-9.09%+47.44% 89.65M
Average -4.95%+9.96%+13.53%-2.15% 322.23M
Weighted average by Cap. -0.14%+4.30%+21.06%-28.21%

Financials

2026 *2027 *
Net sales 30.52M 35.22M 28.58M 26.07M 49.07M 3.36B 49.89M 335M 131M 1.68B 132M 129M 5.61B 34.86M 40.23M 32.64M 29.78M 56.04M 3.84B 56.98M 383M 150M 1.92B 151M 148M 6.41B
Net income - -
Net Debt 1.96M 2.26M 1.83M 1.67M 3.14M 215M 3.2M 21.47M 8.41M 108M 8.47M 8.29M 359M 4.84M 5.59M 4.53M 4.14M 7.78M 533M 7.91M 53.15M 20.82M 267M 20.98M 20.52M 890M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216

Annual profits - Rate of surprise